日本消化器外科学会雑誌第41巻第1号

Similar documents

日本化学療法学会雑誌第58巻第4号

日本化学療法学会雑誌第57巻第5号

アルコール依存症

日本化学療法学会雑誌第57巻第S-2号


目    次

日本化学療法学会雑誌第61巻第6号

日本糖尿病学会誌第58巻第7号

17 (VAP: Ventilator-associated pneumonia) ICU 6 52 [1] VAP 3 4 Streptococcus pneumonia Haemophilus Influenzae Staphylococcus aureus Pseudomonas

4月号 学会特集号 122247/16)一般演題目次



untitled

- 1 -

ヒビスコール液A カタログ

内科96巻3号★/NAI3‐1(第22回試験問題)

CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote



日本化学療法学会雑誌第64巻第4号

Table 1 Epidemiologic characteristics in the elderly patients with sepsis Table 2 Main underlying disease

CHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str

日本化学療法学会雑誌第55巻第S-1号


院内感染対策相談窓口 質疑応答集(平成26年度)

VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus

Fig. 1 Table l l l l l l l l l l l l l l l l l l l l l l l l l l

R06_01

untitled

Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis

CHEMOTHERAPY

ネットワークユーティリティ説明書

「東京都子供・子育て支援総合計画」中間見直し版(案)第2章 子供と家庭をめぐる状況

Microsoft Word - 01マニュアル・入稿原稿p1-112.doc

H28_大和証券_研究業績_C本文_p indd

日本呼吸器学会雑誌第45巻第2号


Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec DNA 2, , % 1.65% 1.17% 90% 9 Escherichia coli -

CHEMOTHERAPY

第5号(2002年)/巻頭

公開情報 2016 年 1 月 ~12 月年報 院内感染対策サーベイランス集中治療室部門 3. 感染症発生率感染症発生件数の合計は 981 件であった 人工呼吸器関連肺炎の発生率が 1.5 件 / 1,000 患者 日 (499 件 ) と最も多く 次いでカテーテル関連血流感染症が 0.8 件 /

VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum

CHGエタノール消毒液1%製品情報_PDF

E. coli E. coli é H. influenzae Helicobacter pylori

DIC vegetation 1 nonbacterial thrombogenic e

SCORE−‹Šp‡Ì”è‹ø‡«Ver3



VOL.36 S-I CHEMOTHERAPY Tabl 1 List of healthy male volunteers



untitled

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent



????? 1

一般社団法人 日本感染症学会 第89回総会資料

Prenention of ventilator-associated pneumonia

日本消化器外科学会雑誌第39巻第2号

CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc

基発0408第2号 東日本大震災に伴う解雇、雇止め等に対する対応について

Acecide_ProductsInformation2010PDF.indd

日本化学療法学会雑誌第65巻第4号


04-c-„FŒ{›xŒ¾-4.01

日本化学療法学会雑誌第57巻第1号

日本化学療法学会雑誌第57巻第4号

IP S ( :H ) ( ) ( :H22 4


CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

in situ Hex

Key words: change serotype, Pseudomonas aeruginosa anti-pseudomonal drug,

日本臨床微生物学雑誌第22巻第3号


CHEMOTHERAPY DEC phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepac

Jpn. I. Oral Biol., 37: , Antimicrobial effects of high oxidation potential water on various microorganisms and an evaluation of mutageni

川名 430 Fig.1 (a) Compressor jet-nebulizer Using the with nasal (Devilbiss nasal inhalation inhalation Pulmo-Aide) and 明彦 他 Fig.2 equipment.(b) Process

JC46601’ÓFC

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human

CHEMOTHERAPY DEC (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecali

第65回日本化学療法学会東日本支部総会 抄録

CHEMOTHERAPY

1272 CHEMOTHERAPY MAR. 1975

2.7 臨床概要

Feb THE JAPANESE JOURNAL OF ANTIBIOTICS Tebipenem pivoxil 1 1, Meiji Seika 2 Meiji Seika G 3 Meiji Seika Tebipen

Table 1 Comparsion of background of the 86 patients with colorectal perforation All Survival Death p-value No. of patients 86 (100%) 74 (86%) 12 (14%)


02-(a)-Łi’ì™·Łv-4.11

PET-CT

.{...book

JAN Fig. 1 Effect of storage on CEC solution (Thin layer cup method B. subtilis PCI-219)

Key words: septic shock, Klebsiella pneumoniae, corticosteroid

上野久美子 他 354 は 高 齢 者 入 院 患 者 の 発 熱 初 期 に お け る病 態 を把 握 し 適 切 な 治 療 が 行 え る よ う に,発 protein 1 Duration of febrile episodes 熱 の 原 因 疾 患, 発 熱 初 日 の 最 高 体

( 23 )

Key words: Disinfectants, Gram negative rods, Bactericidal effect P. aeruginosa 1, P. fluorescens 20 P. putida 179, P. cepacia 216 P. maltophilia 227,

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

第26回日本環境感染学会総会プログラム・抄録集 Part1

Key words: infection stone, biofilm, urease, glycocalyx

Transcription:

Table Profilesofthepatientswithsevereacutepancreatitis Gender(male:female) Age(years) Etiology Alcohol Cholelithiasis Hyperlipidemia Idiopathic Post-ERCP MHLW severityscore(stage) stage stage stage4 SOFA score(mean±sd) APACHE Iscore(mean±SD) Primaryinfectionrates(%) AOSC pneumonia MPgroups(n= 6) 8:8 55( 79) 7 4 8 6 5.±4..±7..5 IPgroups(n= 4) :4 54(4 7) 8 4 7 6 5.8±.4.±5. 7. MHLW severityscore:ministryofhealth,labourandwelfareseverityscore SOFA score:sequentialorganfailureassessmentscore APACHE Iscore:acute physiologyandchronichealthevaluationscore AOSC:acuteobstructivesuppurativecholangitis Table Evaluationofsevereacutepancreatitisby contrastenhancedcomputedtomography Extentofpancreaticnecrosis None <% ~ 5% >5% MP groups 8 IP groups 7 Extentofextrapancreaticinflam mation MP groups 6 IP groups 4 χ

Table StartdayanddurationoftheCRAIandthelocationofthetip ofcatheter Periodsfrom theonsettoastart(days) MPgroups:( ) IPgroups:( ) Period(days) MPgroups:7(5 7) IPgroups:6(5 7) Locationoftipofcatheter Gastroduodenalartery Commonhepaticartery Splenicartery Superiormesentericartery MPgroups(n= 6) IPgroups(n= 4) 6 4 CRAI:continuousregionalarterialinfusion Table4 Theenforcementratesand thestarting daysanddurationdaysofchdf,sdd + EN CHDF Enforcementrates(%) Start(days) Period(days) SDD + EN MPgroups 7.5(n= 6) ( ) (7 4) MPgroups Enforcementrates(%) 6.5(n= ) Start(days) 5( ) IPgroups 4.9(n= 6) ( 6) 8( 4) IPgroups 57.(n= 8) 4( 7) CHDF:continuoushemodiafiltration SDD + EN:selec tivedecontaminationofthedigestivetract+enteralnutri tion

Fig. A:TransitionsintheMHLW severityscores foracutepancreatitisduringintensivecareinthe MPandIPgroups.MHLW severityscore:minis tryofhealth,labourandwelfareseverityscore B:TransitionsintheAPACHE Iscoresforacute pancreatitisduringintensivecareinthempand IP groups.apache Iscore:acutephysiology andchronichealthevaluationscore C:Transitions inthesofa scoresforacutepancreatitisduring intensivecareinthemp andip groups.sofa score:sequentialorganfailureassessmentscore. Methicillin-resistannt staphylococcus

aureusmrsa Enteroccocus facium Pseudomonas aeruginosa Enteroccocus faecalis Clostridium difficile Fig. ChangesintheCRPlevelsduringintensive careinthempandipgroups.crp:c reactive protein. Table5 Theincidenceofthecomplicationandsurgicaltreatmentrates,themortalityintheMPand IPgroups Table6 InfectionsiteintheMPandIPgroups MPgroups IPgroups (n= 6) (n= 4) p-value Infection Pancreatitis-related complication Infected pancreatic necrosis Surgicaltreatment Mortality MPgroups (n= 6) 6(7.5%) (.5%) ( 6.%) ( 6.%) ( 6.%) IPgroups (n= 4) 6(4.9%) (.4%) ( 7.%) (4.%) ( %) p-value Expectoration Catheter Blood Feces(Pseudomembranousenteritis) Pancreaticnecrosis Retroperitoneum Surgicalincision Urinarytract 5 Table7 CausativepathogensisolatedintheMPandIPgroups MPgroups(n= 6) IPgroups(n= 4) p-value Methicilin-resistantstaphylococcusaureus Enterococcusfaecium Pseudomonasaeruginosa Enterococcusfaecalis Clostridium dificile Enterobactoraerogenes Escherichiacoli Bacteroidesfragilis Bacilusspecies Proteusmirabilis 4

MRSA Enteroccocus facium Pseudomonas aeruginosa Enteroccocus faecalis Clostridium difficile

Pseudomonas aeruginosa